| GR00053-A | 2210 | NM_001004340 | LOC440607 | np | sp | none | | no | | Genome stability | A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. | Paulsen et al. | 2009 | 19647519 | Cell line | HeLa | gamma-H2AX phosphorylation and DNA content | Fluorescence | siARRAY human genome siRNA library | Genome-wide | siRNA | p-value | Complex criteria | Confidence groupings from 4 to 1 (highest level of confidence in group 4) | GR00054-A | 2210 | NM_001004340 | LOC440607 | np | 0.779 | none | | no | | Combinatorial effect with paclitaxel | Synthetic lethal screen identification of chemosensitizer loci in cancer cells. | Whitehurst et al. | 2007 | 17429401 | Cell line | NCI-H1155 | Viability (synthetic lethal) | ATP level | # G-005000-01 | Genome-wide | siRNA | Paclitaxel/control ratio | Complex criteria | Additional information about 87 high-confidence hits | GR00056-A | 2210 | NM_001004340 | LOC440607 | np | 0.793 | none | | no | | Melanogenesis | Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. | Ganesan et al. | 2008 | 19057677 | Cell line | MNT-1 | Melanin protein expression and viability | Absorbance and luminescence | rp | Genome-wide | siRNA | Normalized absorbance ratio | > 2 standard deviations below mean | Additional information about a secondary screen (retest to determine false-positive rate) | GR00098-A-1 | 2210 | ENSG00000198019 | LOC440607 | ENSG00000198019 | sp | none | | no | | Cell division (1) | Genome-scale RNAi profiling of cell division in human tissue culture cells. | Kittler et al. | 2007 | 17994010 | Cell line | HeLa | Cell number and DNA content | Laser scanning cytometry | rp | Genome-wide | esiRNA | Complex, sp | Complex criteria | | GR00151-A-1 | 2210 | ENSG00000198019 | FCGR1B | np | -0.463 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. | Słabicki et al. | 2010 | 20613862 | Cell line | HeLa | (HR-DSBR) DR-GFP reporter | Flow cytometry | Custom-made | Genome-wide | esiRNA | Z-score | < -2 OR > 2 | | GR00180-A-1 | 2210 | 440607 | LOC440607 | PL-50089 | 0.872 | none | | no | | Hepatitis C virus replication (1) | A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. | Tai et al. | 2009 | 19286138 | Cell line | Huh7/Rep-Feo | HCV replicon RNA copy number | Luminescence | siARRAY Human Genome siRNA Library | Genome-wide | siRNA | q-value | Complex criteria | | GR00196-A-1 | 2210 | ENSG00000198019 | | np | sp | none | | no | | TP53 interactions (1) | A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. | Krastev et al. | 2011 | 21642980 | Cell line | HCT116 ( wildtype and TP53 knockout) | TP53 protein expression and viability | Fluorescence | rp | Genome-wide | esiRNA | Complex, sp | Complex criteria | | GR00242-A-1 | 2210 | NM_001004340 | LOC440607 | np | sp | none | | no | | Selective autophagy regulation (1) | Image-based genome-wide siRNA screen identifies selective autophagy factors. | Orvedahl et al. | 2011 | 22020285 | Cell line | HeLa/GFP-LC3 | Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression | Fluorescence | siGenome | Genome-wide | siRNA | Z-score | Complex criteria | | GR00244-A | 2210 | | FCGR1B | np | 2.35 | Increased viability with neratinib | | no | | Combinatorial effect with neratinib | A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments. | Seyhan et al. | 2011 | 21487605 | Cell line | SKBR-3 overexpressing ErbB2 | Viability (synthetic lethal) | Microarray | Decode lentiviral-shRNAmir | Genome-wide | shRNA | Fold change | < | False discovery rate cutoff: < | GR00249-S | 2210 | 2210 | FCGR1B | J-181816-09 | 0.32487 | none | | no | number of cells compared to control (%): 94.37 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 2210 | 2210 | FCGR1B | M-181816-00 | -2.07959 | Decreased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 84.53 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 2210 | 2210 | FCGR1B | s194405 | 0.35527 | none | | no | number of cells compared to control (%): 95.91 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 2210 | 2210 | FCGR1B | s194406 | -1.13828 | none | | no | number of cells compared to control (%): 81.97 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 2210 | 2210 | FCGR1B | s5071 | 0.38205 | none | | no | number of cells compared to control (%): 105.67 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00253-A | 2210 | NM_001004340 | LOC440607 | np | -0.244 | none | | | | hepcidin regulation | Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. | Mleczko-Sanecka et al. | 2014 | 24385536 | Cell line | Huh7 | hepcidin::fluc mRNA expression | Luminescence | siGenome siARRAY SMARTpool | Genome-wide | siRNA | Z-score | > | Cutoff < | GR00255-A-1 | 2210 | 2210 | FCGR1B | TRCN0000140388, TRCN0000141454, TRCN0000142209, TRCN0000144765, TRCN0000145147 | -0.270673692 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 2210 | 2210 | FCGR1B | TRCN0000140388, TRCN0000141454, TRCN0000142209, TRCN0000144765, TRCN0000145147 | -0.120028999 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 2210 | 2210 | FCGR1B | TRCN0000140388, TRCN0000141454, TRCN0000142209, TRCN0000144765, TRCN0000145147 | -0.478905602 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 2210 | 2210 | FCGR1B | TRCN0000140388, TRCN0000141454, TRCN0000142209, TRCN0000144765, TRCN0000145147 | -0.428696883 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 2210 | 2210 | FCGR1B | TRCN0000140388, TRCN0000141454, TRCN0000142209, TRCN0000144765, TRCN0000145147 | 0.378487265 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00300-A | 2210 | | FCGR1B | TRCN0000145147, TRCN0000141454, TRCN0000140388, TRCN0000144765, TRCN0000142209 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00303-A | 2210 | NM_001004340 | LOC440607 | np | -0.69 | none | | | | Clear cell renal cell carcinoma (ccRCC) survival regulation | Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target | Gerlinger et al. | 2012 | 22362593 | Cell line | VHL-deficient RCC4 | Proliferation and Viability | Fluorescence | np | Genome-wide | siRNA | Z-score | < | In the phenotype data duplicates were in the original document, which have been removed. | GR00310-A-1 | 2210 | 2210 | LOC440607 | np | 0.55 | none | | | | Sindbis virus (SINV) infection (1) | Genome-Wide RNAi Screen Identifies Novel Host Proteins Required for Alphavirus Entry | Ooi et al. | 2013 | 24367265 | Cell line | U2OS | Sindbis virus (SINV) reporter | Luminescence | Ambion Silencer V3 | Genome-wide | siRNA | Z-score | < -3 OR > 2 | | | 2210 | 2210 | FCGR1B | np | 77.7 | Decreased NF-kappaB reporter expression | | | 74,5% viability | | | | | | | | | | | | | | | | GR00327-A | 2210 | 2210 | FLT4 | CLL-H-010227 | -0.4393240393014412 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 2210 | 2210 | FLT4 | CLL-H-010226 | 0.7014687753539248 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 2210 | 2210 | FLT4 | CLL-H-010225 | -2.713926041511442 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 2210 | 2210 | FLT4 | CLL-H-010228 | -0.00392053842763014 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 2210 | 2210 | FLT4 | CLL-H-010229 | 0.5838908059470682 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00360-A-1 | 2210 | ENSG00000198019 | FCGR1C | 247642 | 0.7916500000000001 | Mildly decreased CFP-tsO45G cell surface transport | | | | Secretory transport (1) | Genome-wide RNAi screening identifies human proteins with a regulatory function in the early secretory pathway | Simpson et al. | 2012 | 22660414 | Cell line | HeLa Kyoto | CFP-tsO45G cell surface transport | Fluorescence | Ambion | Genome-wide | siRNA | Deviation score | < - 1 OR > 0.75 (mild: 0.75 - 1.0; strong: > 1.0) | For validation screen see Secretory transport (2). | | 2210 | 2210 | FCGR1B | | 0 | none | | | | | | | | | | | | | | | | | | | GR00376-A-1 | 2210 | 2210 | FCGR1B | | 0.431974674 | none | | | | Mitigators of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID | GR00376-A-2 | 2210 | 2210 | FCGR1B | | 0.075521775 | none | | | | Sensitizers of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID | GR00378-A | 2210 | | FCGR1B | | -0.914216135 | none | | | | Poliovirus vaccine production | Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game | van der Sanden et al. | 2015 | 26581994 | Cell line | HEp-2C | Infection with Attenuated Poliovirus | ELISA | Dharmacon | Genome-wide | siRNA | Z-score | > | For infection, a single lot of the attenuated Sabin type 2 poliovirus was used for the screen. Gene IDs were not provided, only the gene name/symbol | | 2210 | NM_001004340 | FCGR1B | | 45.421 | none | | | | | | | | | | | | | | | | | | | GR00386-A-1 | 2210 | 2210 | FCGR1B | | 79.331475807422 | none | | | | NOD2 stimulation by MDP | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | Viability | Luminescence | Dharmacon | Genome-wide | siRNA | Percentage growth | Decreased: <70, increased: >120 | Reagent IDs not provided | GR00386-A-2 | 2210 | 2210 | FCGR1B | | -36.2 | none | | | | MDP-induced IL-8 secretion | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | IL-8 secretion | ELISA | Dharmacon | Genome-wide | siRNA | Percent inhibition of IL-8 secretion | Increased: <-300, Decreased: >60 | Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |